Diffuse esophageal eosinophilia tied to more severe EoE, lower steroid response

Share

Patients with eosinophilic esophagitis (EoE) who had diffuse esophageal eosinophilic involvement exhibited greater baseline disease severity and lower histologic and endoscopic response rates to topical corticosteroids than patients with localized disease, according to a retrospective cohort study published online in Clinical Gastroenterology and Hepatology.

Stefani Aleman, MPH, of the University of North Carolina School of Medicine in Chapel Hill, and colleagues evaluated 888 patients with newly diagnosed EoE. They sought to determine whether eosinophilic involvement limited to the proximal or distal esophagus differed from diffuse involvement — at least 15 eosinophils per high-power field in both the proximal and distal esophagus — in disease presentation and treatment outcomes.

Among 395 patients treated with topical corticosteroids, histologic response, defined as fewer than 15 eosinophils per high-power field, occurred in 51% of patients with diffuse involvement, compared with 70% of those with proximal-only involvement and 67% with distal-only involvement. Patients with diffuse disease also had lower endoscopic response rates, although global symptom response did not differ significantly among groups.

Evan S. Dellon, MD, MPH

Evan S. Dellon, MD, MPH, the study’s senior and corresponding author and a professor of medicine at the University of North Carolina School of Medicine, where he directs the Center for Esophageal Diseases and Swallowing, told GI & Hepatology News that diffuse esophageal eosinophilia “is not only associated with increased endoscopic severity, but also decreased response to swallowed topical steroids.”

Because eosinophilic inflammation in EoE is patchy, current guidelines recommend at least six biopsies from at least two esophageal levels, the authors wrote. They noted that peak eosinophil counts have generally not been shown to predict treatment response or correlate with disease severity. Whether the extent of involvement carries more clinical information has been unclear.

Study design and patient characteristics

The researchers analyzed patients of all ages from the University of North Carolina EoE Clinicopathologic database through May 2024. All patients had newly diagnosed EoE and available biopsy data from both proximal and distal esophageal regions. The center’s protocol is to take four biopsy fragments each from the proximal and distal halves of the esophagus, for eight total. Patients previously treated with topical corticosteroids or dietary elimination were excluded.

Esophageal eosinophilic involvement was classified into three groups based on biopsy findings:

  • Diffuse involvement: 623 patients (70%) had eosinophilia in both proximal and distal regions.

  • Distal-only involvement: 194 patients (22%) had eosinophilia confined to the distal esophagus.

  • Proximal-only involvement: 71 patients (8%) had eosinophilia confined to the proximal esophagus.

The researchers compared baseline demographics, symptoms, atopic conditions, endoscopic findings, and disease severity across the groups. They also examined treatment outcomes after topical corticosteroid therapy or food elimination diets.

Patients with diffuse involvement were younger at diagnosis, with a mean age of 26.7 years, compared with 29.0 years for proximal-only involvement and 30.5 years for distal-only involvement. Demographic characteristics, body mass index, concomitant atopic conditions, family history, and symptom duration were generally similar across groups.

Baseline endoscopic findings and severity

Patients with diffuse eosinophilic involvement had more severe inflammatory endoscopic findings than those with localized disease. Mean Eosinophilic Esophagitis Endoscopic Reference Scores (EREFS), which range from 0 to 9, were 4.0 in patients with diffuse involvement, compared with 2.8 in the proximal-only group and 2.7 in the distal-only group.

Exudates were reported in 61% of patients with diffuse involvement, compared with 43% with proximal-only and 36% with distal-only involvement. The corresponding figures were 58%, 49%, and 43% for rings; 67%, 42%, and 45% for edema; and 88%, 75%, and 70% for furrows.

Although the prevalence of esophageal strictures did not differ significantly among groups, patients with diffuse involvement who required dilation had smaller stricture diameters. Mean diameters were 11.6 mm in the diffuse group, compared with 12.7 mm in the proximal-only group and 13.1 mm in the distal-only group.

Overall disease severity, measured using the Index of Severity for Eosinophilic Esophagitis, was also greater among patients with diffuse involvement. Mean scores were 9.3 in the diffuse group, compared with 8.1 and 7.8 in the proximal-only and distal-only groups, respectively.

In the diffuse group, 45% of patients had moderate disease and 14% had severe disease. The rates were 41% and 10%, respectively, in the proximal-only group and 30% and 12% in the distal-only group.

After adjustment for potential confounders, younger age, exudates, rings, edema, furrows, and greater disease severity remained independently associated with diffuse eosinophilic involvement.

Topical corticosteroid response

The researchers evaluated 395 patients who received swallowed topical corticosteroids and underwent follow-up endoscopy with biopsies after eight to 12 weeks.

Treatment consisted of swallowed fluticasone administered through an inhaler or aqueous budesonide mixed into a slurry, at doses of 1 mg to 2 mg per day. No patients received the FDA-approved budesonide oral suspension, which was not available during the study period. The specific corticosteroid and prescribed doses did not differ significantly across groups.

Patients with diffuse involvement had lower histologic response rates at all three thresholds evaluated: fewer than 15, 6 or fewer, and fewer than 1 eosinophil per high-power field. At 6 or fewer eosinophils, response rates were 43% with diffuse involvement, compared with 67% with proximal-only and 60% with distal-only involvement. At fewer than 1 eosinophil, the rates were 25%, 53%, and 43%, respectively.

After adjustment for other predictors of response, including body mass index, age at diagnosis, and baseline endoscopic severity, diffuse involvement remained associated with lower odds of histologic response (adjusted odds ratio, 0.47).

Following treatment, mean EREFS remained higher in patients with diffuse involvement (2.5) than in those with proximal-only (1.8) or distal-only (1.5) involvement. An endoscopic response, defined as an EREFS of 2 or lower, occurred in 58% of patients with diffuse involvement, compared with 70% of those with proximal-only involvement and 81% with distal-only involvement.

Global symptom response was documented by providers and available for 166 patients. Despite the differences in histologic and endoscopic outcomes, it did not differ significantly among the groups: 81% with distal-only, 73% with proximal-only, and 73% with diffuse involvement.

Food elimination diet outcomes

The researchers separately evaluated 235 patients treated with food elimination diets who underwent follow-up endoscopy and biopsy after six to eight weeks. Dietary approaches included empiric elimination, allergy test-directed elimination, and elemental diets, with most patients receiving empiric elimination.

Unlike the topical corticosteroid findings, histologic response rates did not differ significantly by disease distribution.

Histologic response at the threshold of fewer than 15 eosinophils per high-power field occurred in 37% of patients with diffuse involvement versus 44% with localized involvement.

Global symptom response also did not differ significantly between groups. However, endoscopic severity remained greater among patients with diffuse disease. An EREFS of 2 or lower was achieved by 48% of patients with diffuse involvement, compared with 75% of those with localized involvement.

The researchers cautioned that dietary strategies varied substantially, limiting conclusions about the relationship between disease distribution and response to food elimination.

Interpretation and study limitations

The researchers noted that previous studies examining the relationship between esophageal eosinophil distribution and treatment response have yielded mixed results. A post hoc analysis of a clinical trial of budesonide orodispersible tablets, an esophageal-specific formulation, found no difference in histologic response by extent of disease involvement.

The authors offered a potential explanation for the difference. Patients in their cohort used off-label topical corticosteroid formulations, which may not coat the esophagus as uniformly as formulations specifically developed for esophageal delivery.

The authors suggested that differences in preparation, dosing, and adherence of medication to the esophageal mucosa could contribute to uneven drug delivery, which could be problematic in diffuse disease.

However, the authors acknowledged that patients with distal-only involvement responded better than those with diffuse disease, which might not be expected if drug delivery to the distal esophagus were the problem. They also noted that most prior data on predictors of topical steroid response come from off-label formulations, and that esophageal-specific formulations may mitigate some of these factors.

The study had several limitations. Its retrospective, single-center design may limit generalizability. Validated patient-reported outcome measures were unavailable, and symptom response relied on provider documentation in medical records.

The EoE Histological Scoring System was unavailable, and findings such as basal zone hyperplasia, dilated intercellular spaces, and lamina propria fibrosis were inconsistently reported.

Food elimination strategies were heterogeneous, and the numbers of patients receiving specific dietary approaches were too small for meaningful subgroup analyses.

The authors wrote that sampling error was unlikely, given the center’s consistent practice of obtaining eight biopsies. They noted, however, that biopsies assessed only mucosal involvement and could not characterize disease extending into deeper esophageal layers.

Stefani Aleman, MPH

The researchers also could not determine whether diffuse involvement represented a distinct biological phenotype or reflected greater overall inflammatory burden.

Aleman, the study’s lead author and a medical student at the UNC School of Medicine, said the findings need confirmation in larger prospective, multicenter cohorts. “Biopsy sampling can be variable, and a standardized definition of diffuse disease would be helpful. Future work should examine whether distribution of eosinophilia also predicts response to other therapies and if biological mechanisms drive this pattern,” she told GI & Hepatology News.

Implications for clinical practice

Aleman identified two potential implications for clinical practice.

“First, these findings support separating proximal and distal esophageal biopsies into two jars,” Aleman said. “This is not mandatory for diagnosis or follow-up, but it provides useful information on severity and prognosis, and pathology reports can then note the extent of involvement. Second, alongside other clinical predictors such as severe disease or need for dilation, diffuse involvement may help predict response to topical steroids and inform treatment selection. It may serve as a simple, readily available marker of a more severe phenotype.”

Aleman also said that knowing whether a patient has diffuse disease could help clinicians counsel patients about their likelihood of responding to topical steroids and guide the choice of initial therapy. “For patients with diffuse involvement, clinicians may want to monitor more closely for steroid non-response and consider earlier escalation or alternative therapies, such as biologics, when response is inadequate,” she said.

In the paper, the authors wrote that diffuse involvement and other known predictors of topical steroid response “are not yet sufficient to guide clinical decision-making.” They added that the predictors are still important information for discussions with individual patients.

Kristle Lee Lynch, MD

Expert insight

Kristle Lee Lynch, MD, was not involved in the study. She is a professor of clinical medicine and director of the Esophageal and Swallowing Center, the GI Physiology Lab, and the Advanced Esophagology Fellowship in the Division of Gastroenterology at the University of Pennsylvania Perelman School of Medicine.

“This study provides novel insights into localized versus diffuse esophageal eosinophilia in EoE and reinforces taking biopsies from multiple levels of the esophagus to diagnose EoE,” she told GI & Hepatology News. “Diffuse esophageal eosinophilia could identify patients with more severe disease who need earlier consideration of advanced therapies. Further research is warranted to guide individualized therapeutic strategies for patients with EoE.”

Dr. Dellon reported financial relationships with more than 40 companies, including research funding and consulting fees from Adare/Ellodi, AstraZeneca, Dr. Falk Pharma, GSK, Regeneron, Sanofi, and Shire/Takeda. Reed reported consulting fees from AstraZeneca and GI Reviewers. The other authors reported no disclosures. The study was supported in part by the National Institutes of Health.